Vaccine constituents used for immunization in 4 groups of 8 rhesus macaques per group of rhesus macaques at 0, 4, 8 and 16 weeks administered by the SC route in all except group 4 IM, group 5 was unimmunized.

Animals in group 1 consisted of 8 animals (except group 4 had 6 animals) challenged with SHIVSF162.P4 grown in C8166-CCR5+ T cells (HLA*A01, DR*04). All vaccine components were biotinylated, linked to streptavidin-bound dextran and formulated into an emulsion with the TiterMax adjuvant (except group 4 and 5).实验动物分为多个实验组，第1组共包含8只受试动物，第4组仅含6只，所有受试动物均经在C8166-CCR5阳性T淋巴细胞（HLA*A01、DR*04型）中培养增殖的SHIVSF162.P4毒株（猴-人免疫缺陷病毒SF162.P4株，Simian-Human Immunodeficiency Virus SF162.P4）攻毒。所有疫苗组分均经过生物素化修饰，结合至链霉亲和素耦联的葡聚糖，并与TiterMax佐剂配制成乳剂，第4组与第5组除外。